Nuria’s funding, which was announced at the beginning of 2018, will support the project ‘Generation of Isogenic Models of Clear Cell Renal Cell Carcinoma using CRISPR-engineered Kidney Organoids, for the identification of diagnostic biomarkers’. The three years of ‘Ayudas LAB’ support, which is for emerging groups carrying out projects that have obvious translational possibilities, will enable Nuria’s Pluripotency for Organ Regeneration group to work together with researchers and clinicians at Vall d’Hebron Institut d’Oncologia, ICO-IDIBELL and Hospital Clinic de Barcelona on the project.
Aranzazu’s project, ‘Neuroblastoma en un chip para investigar la resistencia a fármacos y el uso de nanopartículas terapéuticas’, will be carried out in Josep Samitier’s Nanobioengineering group starting at the end of this year and is funded under the Investigador AECC call, a career development award for transitioning senior researchers. It will aim to build biomimetic models to investigate the resistance of tumors to different therapies, as well as the mechanisms that lead to the formation of vasculature in cancer.
